FITC Annexin V Apoptosis Detection Kit with PI

Pricing & Availability
Regulatory Status
Other Names
Annexin A5 Apoptosis Detection Kit
Ave. Rating
Submit a Review
Product Citations
Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours at 37°C, then stained with Annexin V- FITC for 15 minutes at 37°C in Annexin V Binding buffer. Propidium Iodide (PI) (cat. 421301 at 0.03 µg/Test) was added 5 minutes prior to running tubes.
  • FITC_Annexin-V_kit_052318
    Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours at 37°C, then stained with Annexin V- FITC for 15 minutes at 37°C in Annexin V Binding buffer. Propidium Iodide (PI) (cat. 421301 at 0.03 µg/Test) was added 5 minutes prior to running tubes.
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
640914 100 tests £174
Check Availability

Need larger quantities of this item?
Request Bulk Quote

BioLegend's FITC Annexin V Apoptosis Detection Kit with PI has been specifically designed for the identification of apoptotic and necrotic cells.

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer is recommended for use with Annexin V staining. Annexin V binding alone cannot differentiate between apoptotic and necrotic cells. To help distinguish between the necrotic and apoptotic cells we recommend use of our Propidium Iodide Solution (PI). Early apoptotic cells will exclude PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Propidium iodide is a fluorescent dye that binds to DNA. When excited by 488 nm laser light, it can be detected with in the PE/Texas Red® channel with a bandpass filter 610/10. It is commonly used in evaluation of cell viability or DNA content in cell cycle analysis by flow cytometry.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
All mammalian species
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
Store between 2°C and 8°C. Do not freeze.

Caution: Propidium Iodide Solution is toxigenic and mutagenic; handle with care.

FC - Quality tested

Recommended Usage

Staining Procedure:
1. Wash cells twice with cold BioLegend's Cell Staining Buffer, and then resuspend cells in Annexin V Binding Buffer at a concentration of 0.25-1.0 x 107 cells/mL.
2. Transfer 100 µL of cell suspension in a 5 mL test tube.
3. Add 5 µL of FITC Annexin V.
4. Add 10 µL of Propidium Iodide Solution.
5. Gently vortex the cells and incubate for 15 min at room temperature (25°C) in the dark.
6. Add 400 µL of Annexin V Binding Buffer to each tube. Analyze by flow cytometry with proper machine settings.

Application Notes

Materials Provided:
0.5 ml of FITC Annexin V
1 ml of Propidium Iodide Solution
50 ml of Annexin V Binding Buffer

Materials Not Included:
Cell Staining Buffer (Cat. No. 420201)

For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Ranhanathan P, et al. 2013. J AM Soc Nephrol. PubMed
  2. Yu J, et al. 2014. PloS One. 9:114650. PubMed
  3. Wang Y, et al. 2014. Biochem Biophys Res Commun. 456:656. PubMed
  4. Jaishy B, et al. 2015. J Lipid Res. 56:546. PubMed
Product Citations
  1. Su T, et al. 2021. Metabolites. 11:. PubMed
  2. Tiu GC, et al. 2021. Dev Cell. 56:2089. PubMed
  3. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  4. Ho J, et al. 2016. PLoS Biol. 14:e2000117. PubMed
  5. Markowicz-Piasecka M, et al. 2020. Apoptosis. 25:426. PubMed
  6. Lyu X, et al. 2019. Oncol Rep. 41:3137. PubMed
  7. Fang H, et al. 2022. Exp Ther Med. 24:440. PubMed
  8. Chen J, et al. 2021. Antioxidants (Basel). 10:. PubMed
  9. Shimonosono M, et al. 2021. Biomolecules. 11:. PubMed
  10. Wang C, et al. 2021. Clin Transl Med. 11:e522. PubMed
  11. Li MM, et al. 2018. Int J Infect Dis. 70:72. PubMed
  12. Xie T, et al. 2021. Ann Transl Med. 9:1249. PubMed
  13. Kocak P, et al. 2021. Macromol Biosci. 21:e2000287. PubMed
  14. Li D, et al. 2022. Sci Adv. 8:eabm0478. PubMed
  15. Yuan L, et al. 2015. Endocr Relat Cancer. 22: 577 - 591. PubMed
  16. Belo H, et al. 2015. PLoS One. 10: e0139740. PubMed
  17. Morita K, et al. 2020. Cell. 702:181. PubMed
  18. Yang J, et al. 2021. Oncoimmunology. 1875638:10. PubMed
  19. Guo Q, et al. 2018. Front Immunol. 9:1197. PubMed
  20. Soonthornchai W, et al. 2019. Asian Pac J Allergy Immunol. N/A. PubMed
  21. Son Y, et al. 2020. Mol Metab. 39:101005. PubMed
  22. Choromanska A, et al. 2020. Biomed Rep. 13:32. PubMed
  23. Mahmoud A, et al. 2016. Int J Toxicol. 35: 429 - 437. PubMed
  24. Liu J, et al. 2015. Biochem Biophys Res Commun. 463: Pags 262-267. PubMed
  25. Wang Y, et al. 2014. Biochem Biophys Res Commun. 456:656. PubMed
  26. Neumann CKA, et al. 2020. Mol Metab. 34:136. PubMed
  27. Ali DM, et al. 2019. Cell Death Discov. 5:128. PubMed
  28. Yao J, et al. 2018. Onco Targets Ther. 11:3793. PubMed
  29. Vashist A, et al. 2022. Asian Pac J Cancer Prev. 23:3629. PubMed
  30. Chang T, et al. 2016. Sci Rep. 6:23403. PubMed
  31. Shao M, et al. 2018. Evid Based Complement Alternat Med. 2018:6049498. PubMed
  32. Coelho CC, et al. 2019. Sci Rep. 9:11050. PubMed
  33. Orgaz JL, et al. 2020. Cancer Cell. 37:85. PubMed
  34. Zhang W, et al. 2021. J Clin Invest. 131:. PubMed
  35. Kang DY, et al. 2022. J Oncol. 2022:6737248. PubMed
  36. Korencak M, et al. 2019. JCI Insight. 4. PubMed
  37. Shen L, et al. 2021. Cell Death Discov. 7:392. PubMed
  38. Lian W, et al. 2022. J Immunol Res. 2022:3129765. PubMed
  39. Saboor-Maleki S, et al. 2016. Technol Cancer Res Treat. 10.1177/1533034616650119. PubMed
  40. Tatsuno K, et al. 2019. Cell Death Dis. 10:578. PubMed
  41. Ouyang J, et al. 2019. J Surg Res. 233:221. PubMed
  42. Xiao Y, et al. 2020. Nucleic Acids Res. 48:11113. PubMed
  43. Kiss E, et al. 2021. Int J Mol Sci. 22:. PubMed
  44. Wu J, et al. 2020. Immunity. 53:115. PubMed
  45. Sareddy G, et al. 2016. Sci Rep. 6: 24185. PubMed
  46. Xie L, et al. 2020. Front Oncol. 1.354166667. PubMed
  47. Fei X, et al. 2019. Cancer Manag Res. 11:4781. PubMed
  48. Balachandran C, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.06.096. PubMed
  49. Chen J, et al. 2021. J Oncol. 2021:5572402. PubMed
  50. Cao W, et al. 2016. Nat Commun. 7:11687. PubMed
  51. Finetti F, et al. 2020. Cell Death Differ. 27:310. PubMed
  52. Xing W, et al. 2020. J Recept Signal Transduct Res. 1:. PubMed
  53. Virumbrales–Muñ oz M, et al. 2019. Sci Rep. 9:6199. PubMed
  54. Allur Subramaniyan S, et al. 2018. Cell Commun Adhes. 24:19. PubMed
  55. Perez E, et al. 2020. J Immunol. 205:2489. PubMed
  56. Callender LA, et al. 2021. Nat Commun. 12:3379. PubMed
  57. Liu R, et al. 2021. Oncol Lett. 21:06. PubMed
  58. Changizi V, et al. 2021. Iran J Med Sci. 46:291. PubMed
  59. Zhang N, et al. 2021. Atherosclerosis. 334:39. PubMed
  60. Blue E, et al. 2015. Diabetes. 64: 2664 - 2675. PubMed
  61. Kongkavitoon P, et al. 2016. PLoS One. 11: 0146696. PubMed
  62. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  63. Sohrabi Y, et al. 2019. Front Immunol. 9:3155. PubMed
  64. Soonthornchai W, et al. 2021. Sci Rep. 11:14186. PubMed
  65. Hu K, et al. 2020. Nat Commun. 2778:11. PubMed
  66. Jaishy B, et al. 2015. J Lipid Res. 56:546. PubMed
  67. Shin JJ, et al. 2020. Cell Rep. 32:108093. PubMed
  68. Patil M, et al. 2021. Circ Res. 129:1006. PubMed
  69. Abokyi S, et al. 2021. Int J Mol Sci. 22:. PubMed
  70. Still C 2nd, et al. 2021. Cell Reports Medicine. 2(7):100343. PubMed
  71. Tailor D, et al. 2020. Br J Cancer. . PubMed
  72. Ryva B, et al. 2019. Front Oncol. 9:100. PubMed
  73. Flegkas A, et al. 2019. Medicines (Basel). 6:1. PubMed
  74. Wu A, et al. 2020. Cell Death Dis. 11:40. PubMed
  75. Huang S, et al. 2022. J Cancer. 13:2662. PubMed
  76. Merikhian P, et al. 2022. Mol Oncol. 16:485. PubMed
  77. Zhou Y, et al. 2021. NPJ Regen Med. 6:34. PubMed
  78. Wang YL, et al. 2021. Environ Health Perspect. 129:57003. PubMed
  79. Zhou L, et al. 2021. Front Oncol. 11:668617. PubMed
  80. Dudek M, et al. 2021. Nature. 592:444. PubMed
  81. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  82. Ma H, et al. 2015. Sci Rep. 5: 15121. PubMed
  83. Kan L, et al. 2015. PLoS One. 10: 0144513. PubMed
  84. Viereckl MJ, et al. 2022. Biomolecules. 12:. PubMed
  85. Roupakia E, et al. 2021. Cancers (Basel). 13:. PubMed
  86. Pires D, et al. 2021. Front Immunol. 12:647728. PubMed
  87. Zhou Q, et al. 2020. J Invest Dermatol. . PubMed
  88. Chou ST, et al. 2020. Chin Med. 0.678472222. PubMed
  89. Weiss R, et al. 2015. Innate Immunity. 21: 813 - 826. PubMed
  90. Yu J, et al. 2014. PLoS One. 9:114650. PubMed
  91. Wang JS, et al. 2021. Nat Commun. 12:6271. PubMed
  92. Li XR, et al. 2020. Neoplasma. 67:982. PubMed
  93. Zakharova I, et al. 2022. Front Bioeng Biotechnol. 10:772981. PubMed
  94. Yang Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  95. Lonardi S, et al. 2020. Cancer Immunol Res. 829:8. PubMed
  96. Cho S, et al. 2019. Transl Oncol. 0.820138889. PubMed
  97. Zamani K, et al. 2021. BMC Biotechnol. 21:68. PubMed
  98. Biadglegne F, et al. 2021. Mol Med Rep. 24:. PubMed
  99. Choromanska A, et al. 2020. Pharmaceutics. 12:00. PubMed
  100. Levy G, et al. 2015. PLoS One. 10: 0136070. PubMed
  101. Li C, et al. 2018. Cell Physiol Biochem. 45:366. PubMed
  102. Wang X, et al. 2020. Onco Targets Ther. 13:1691. PubMed
  103. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  104. Lauko A, et al. 2022. Cell Rep. 40:111348. PubMed
  105. Zhong X, et al. 2021. Oncol Lett. 245:21. PubMed
  106. Wang W, et al. 2020. Cancer Cell Int. 1.06875. PubMed
  107. Lin B, et al. 2020. Mol Med Rep. 21:2171. PubMed
  108. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 3    Revision Date: 04/20/2020

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.


*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.


8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account